+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Testing Market - Global Forecast to 2030- Product Image
Respiratory Disease Testing Market - Global Forecast to 2030- Product Image
Sale

Respiratory Disease Testing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012368
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Testing Market grew from USD 6.49 billion in 2024 to USD 6.86 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 9.18 billion by 2030.

The global respiratory disease testing arena is undergoing a dynamic evolution driven by technological breakthroughs, shifting regulatory landscapes, and a heightened focus on early detection and comprehensive disease management. As key stakeholders-from diagnostic laboratories and hospitals to research centers and home care providers-seek to optimize diagnostic accuracy and patient outcomes, understanding the foundational drivers and emerging trends becomes paramount. This executive summary delivers a concise yet thorough overview of the current environment, outlines the transformative forces at play, and highlights strategic insights to inform decision-making. Transitioning from traditional reliance on basic imaging and spirometry, the field now embraces advanced molecular diagnostics and digital health solutions, paving the way for tailored therapies and proactive monitoring. By integrating these developments into an actionable framework, decision-makers can navigate market complexities with confidence and identify opportunities for differentiation and growth.

Transformative Forces Redefining Respiratory Testing

The landscape has witnessed transformative shifts fueled by four primary catalysts. First, digital innovation has redefined diagnostic pathways: artificial intelligence-enhanced imaging platforms and remote monitoring sensors are accelerating detection while reducing clinical burden. Second, decentralization of testing is on the rise as home care settings and point-of-care instruments empower patients and caregivers to conduct pulmonary function assessments outside traditional clinical settings. Third, regulatory harmonization and evolving reimbursement schemes are incentivizing adoption of high-precision assays, particularly molecular diagnostics for infectious respiratory diseases. Finally, the COVID-19 pandemic has underscored the necessity for scalable testing infrastructure, prompting investment in flexible reagent platforms and multiplex immunoassays that can adapt to emerging pathogens. Together, these shifts are not only expanding market scope but also fostering a more patient-centric model where early screening, continuous monitoring, and prognostic evaluation coalesce into a unified care continuum.

Analyzing the 2025 U.S. Tariff Impacts on Supply Chains and Costs

The introduction of new U.S. tariffs in 2025 has introduced a layer of complexity affecting supply chains and cost structures. Imports of key reagents and diagnostic instruments have experienced increased duties, compelling manufacturers and distributors to reassess sourcing strategies. Several global vendors have begun relocating certain production lines closer to North American markets or negotiating tariff exemptions on critical components. Distribution partners are revising pricing models to maintain margin integrity without deterring end-user adoption. Meanwhile, end users in hospitals and research laboratories face incremental budget pressures, which has spurred interest in reagent rental programs and reagent-on-demand models that align costs with actual usage. In response, industry participants are diversifying regionally sourced reagents and enhancing local service support to preserve uptime and minimize the financial impact of import levies.

In-Depth Segmentation Reveals Growth Drivers and Opportunities

Careful segmentation reveals nuanced growth pockets and areas of potential disruption. When the market is studied by test type, blood tests remain foundational, imaging tests-encompassing chest X-ray and computed tomography-drive high capital investments, and pulmonary function tests sustain steady demand for both diagnostic and monitoring purposes. Component analysis unpacks instruments as long-term assets, reagents & kits as recurring revenue drivers, and software as a fast-growing enabler of connectivity and data analytics. By age group, adults account for the largest volume, geriatrics present untapped monitoring needs, and pediatrics demand tailored protocols and low-radiation imaging options. Technology segments underscore the ascent of molecular diagnostics and immunoassays alongside established microbiology methods and advanced imaging technologies. Examining test purpose, diagnosis remains the primary objective, while monitoring, prognosis, and early screening gain prominence in chronic disease management frameworks. Disease-type dissection highlights asthma and chronic obstructive pulmonary disease-subdivided into chronic bronchitis and emphysema-alongside infectious respiratory diseases such as influenza, pneumonia, and tuberculosis, and the rising focus on lung cancer screening. Finally, end-user review shows hospitals & clinics and diagnostic laboratories as core revenue sources, with home care settings and research laboratories expanding footprints.

Comparative Regional Analysis Illuminates Market Variations

Regional dynamics vary considerably across the Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific. In the Americas, robust reimbursement schemes and a dense network of diagnostic centers foster adoption of premium imaging technologies and sophisticated immunoassays. EMEA’s heterogeneous regulatory environment incentivizes center-of-excellence models in leading nations while opening growth corridors in emerging markets through public-private partnerships and digital health initiatives. Asia-Pacific stands out for its capacity to rapidly scale molecular diagnostic labs and leverage mobile screening units in underserved areas. Collaborative networks between hospitals and reference laboratories are driving innovation in all regions, but local market conditions-from tariff structures to healthcare funding priorities-determine the pace and scale of new technology rollouts.

Competitive Landscape and Strategic Initiatives of Key Players

Leading industry participants are actively shaping competitive dynamics. Abbott Laboratories and Thermo Fisher Scientific continue to advance multiplex molecular platforms, while F. Hoffmann-La Roche Ltd. and bioMérieux PLC focus on next-gen immunoassay portfolios. GE Healthcare, Fujifilm Holdings, and Koninklijke Philips N.V. emphasize AI-driven imaging enhancements, and Siemens Healthineers AG integrates software and analytics to optimize workflow. QIAGEN Group and Seegene Inc. specialize in infectious disease panels, bolstered by Eurofins Viracor, LLC’s contract testing expertise. Becton, Dickinson and Company and Bio-Rad Laboratories, Inc. strengthen reagent and kit offerings, while Medtronic PLC and ResMed deliver home diagnostics and remote monitoring solutions. Charles River Laboratories and SDI Diagnostics, Inc. support preclinical and translational research, and COSMED srl and MGC Diagnostics Corporation by Caire Inc. provide niche pulmonary function systems. AstraZeneca PLC leverages strategic partnerships for companion diagnostics, and Thermo Fisher’s ecosystem synergy extends into reagent rental programs.

Actionable Strategies for Strengthening Market Position

Industry leaders should pursue a tri-pronged approach. First, enhance supply chain resilience by diversifying sourcing footprints and establishing local manufacturing or reagent-on-demand partnerships to mitigate tariff volatility. Second, invest in integrated digital platforms that link molecular, immunoassay, and imaging data streams to deliver holistic patient profiles, supporting personalized treatment pathways. Third, cultivate collaborations with payers and regulatory bodies to shape reimbursement policies that reward preventive screening and continuous monitoring, particularly in geriatrics and chronic respiratory conditions. Simultaneously, expand training programs for end users in home care settings and research laboratories to accelerate adoption of remote monitoring tools and point-of-care assays. By executing these recommendations in parallel, organizations can fortify market leadership, drive revenue stability, and enhance patient outcomes.

Conclusion and Path Forward

In sum, the respiratory disease testing market stands at an inflection point where technological innovation, regulatory evolution, and shifting care models converge. Stakeholders who proactively adapt to evolving tariff regimes, leverage advanced diagnostic modalities, and align product portfolios with nuanced segmentation insights can unlock sustained growth. Embracing integrated digital ecosystems and fostering strategic partnerships will be key to delivering value across the entire diagnostic continuum. As the industry pivots toward patient-centric and data-driven paradigms, those who balance operational agility with deep clinical expertise will emerge as frontrunners in shaping the future of respiratory healthcare.

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood Tests
  • Imaging Tests
    • Chest X-Ray
    • Computed Tomography
  • Pulmonary Function Tests
  • Instruments
  • Reagents & Kits
  • Software
  • Adults
  • Geriatrics
  • Pediatrics
  • Imaging Technologies
  • Immunoassays
  • Microbiology
  • Molecular Diagnostics
  • Diagnosis
  • Monitoring
  • Prognosis
  • Screening
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Chronic Bronchitis
    • Emphysema
  • Infectious Respiratory Diseases
    • Influenza
    • Pneumonia
    • Tuberculosis
  • Lung Cancer
  • Diagnostic Laboratories
  • Home Care Settings
  • Hospitals & Clinics
  • Research Laboratories

This research report categorizes the Respiratory Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Respiratory Disease Testing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Disease Testing Market, by Test Type
8.1. Introduction
8.2. Blood Tests
8.3. Imaging Tests
8.3.1. Chest X-Ray
8.3.2. Computed Tomography
8.4. Pulmonary Function Tests
9. Respiratory Disease Testing Market, by Component
9.1. Introduction
9.2. Instruments
9.3. Reagents & Kits
9.4. Software
10. Respiratory Disease Testing Market, by Age Group
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Respiratory Disease Testing Market, by Technology
11.1. Introduction
11.2. Imaging Technologies
11.3. Immunoassays
11.4. Microbiology
11.5. Molecular Diagnostics
12. Respiratory Disease Testing Market, by Test Purpose
12.1. Introduction
12.2. Diagnosis
12.3. Monitoring
12.4. Prognosis
12.5. Screening
13. Respiratory Disease Testing Market, by Diseases Type
13.1. Introduction
13.2. Asthma
13.3. Chronic Obstructive Pulmonary Disease (COPD)
13.3.1. Chronic Bronchitis
13.3.2. Emphysema
13.4. Infectious Respiratory Diseases
13.4.1. Influenza
13.4.2. Pneumonia
13.4.3. Tuberculosis
13.5. Lung Cancer
14. Respiratory Disease Testing Market, by End Users
14.1. Introduction
14.2. Diagnostic Laboratories
14.3. Home Care Settings
14.4. Hospitals & Clinics
14.5. Research Laboratories
15. Americas Respiratory Disease Testing Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Respiratory Disease Testing Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Respiratory Disease Testing Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AstraZeneca PLC
18.3.3. Becton, Dickinson and Company
18.3.4. Bio-Rad Laboratories, Inc.
18.3.5. Biomérieux PLC
18.3.6. Charles River Laboratories
18.3.7. COSMED srl
18.3.8. Eurofins Viracor, LLC
18.3.9. F. Hoffmann-La Roche Ltd.
18.3.10. Fujifilm Holdings
18.3.11. GE Healthcare
18.3.12. Koninklijke Philips N.V
18.3.13. Medtronic PLC
18.3.14. MGC Diagnostics Corporation by Caire Inc.
18.3.15. QIAGEN Group
18.3.16. ResMed
18.3.17. SDI Diagnostics, Inc.
18.3.18. Seegene Inc.
18.3.19. Seimens Healthineers AG
18.3.20. Thermo Fisher Scientific
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. RESPIRATORY DISEASE TESTING MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY DISEASE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 77. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 79. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 81. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 82. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 85. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 87. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 88. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 97. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 131. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 132. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 133. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 134. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 137. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 139. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 140. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 141. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 143. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 144. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 147. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 148. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 149. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 150. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 159. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 162. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 164. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 167. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 169. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 170. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 219. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 222. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 224. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 227. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 228. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 229. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 230. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 239. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 252. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 255. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 258. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 259. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 260. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 261. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 263. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 265. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 270. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 271. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 273. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 275. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 278. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 279. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 280. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 281. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 283. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 285. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 288. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 290. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 291. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 295. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 298. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 299. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 300. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 301. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULM

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

Methodology

Loading
LOADING...

Related Topics

Related Reports

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Respiratory Disease Testing Market Report 2025 - Product Image

Respiratory Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Disease Testing - Global Strategic Business Report - Product Image

Respiratory Disease Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
2024-2029 Global Respiratory Diseases Diagnostic Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities - Product Image

2024-2029 Global Respiratory Diseases Diagnostic Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

  • Report
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From

About the Market

The Respiratory Disease Test market within the context of Diagnostics is a rapidly growing sector, as respiratory diseases are among the most common illnesses worldwide. Tests for respiratory diseases are used to diagnose and monitor a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. These tests can be conducted in a variety of ways, including imaging tests, pulmonary function tests, and laboratory tests. Imaging tests such as X-rays and CT scans are used to detect abnormalities in the lungs, while pulmonary function tests measure the amount of air a person can inhale and exhale. Laboratory tests, such as sputum tests, are used to detect the presence of bacteria or viruses in the lungs. Some companies in the Respiratory Disease Test market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.